298,086 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 298,086 shares of the company's stock, valued at approximately $1,082,000. GSA Capital Partners LLP owned approximately 0.11% of Autolus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of AUTL. BNP Paribas Financial Markets grew its stake in shares of Autolus Therapeutics by 2,603.8% in the first quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company's stock worth $736,000 after purchasing an additional 111,131 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth $127,000. EntryPoint Capital LLC grew its stake in shares of Autolus Therapeutics by 113.6% in the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock worth $137,000 after purchasing an additional 11,456 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Autolus Therapeutics by 117.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company's stock worth $21,532,000 after purchasing an additional 1,824,592 shares in the last quarter. Finally, Avoro Capital Advisors LLC bought a new position in shares of Autolus Therapeutics in the first quarter worth $78,765,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Trading Up 2.3 %

AUTL stock traded up $0.07 during trading hours on Friday, hitting $3.08. 2,714,678 shares of the stock traded hands, compared to its average volume of 1,442,195. The stock has a 50-day simple moving average of $3.91 and a 200 day simple moving average of $3.98. Autolus Therapeutics plc has a one year low of $2.94 and a one year high of $7.45. The company has a market cap of $819.56 million, a P/E ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) earnings per share. Analysts forecast that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on AUTL. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a research note on Friday. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.45.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.